Evidence map›Paper›PMID 39485844›Full record

ArticleScience advances2024

A dual role for PSIP1/LEDGF in T cell acute lymphoblastic leukemia.

Lisa Demoen, Filip Matthijssens, Lindy Reunes, Bruno Palhais, Béatrice Lintermans, Sara T'Sas, Igor Fijalkowski, Joachim Taminau, Muluembet Z Akele, Siska Van Belle and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Lisa DemoenLab of Normal and Malignant Hematopoiesis, Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0001-7035-0266
Filip MatthijssensLab of Normal and Malignant Hematopoiesis, Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.
Lindy ReunesLab of Normal and Malignant Hematopoiesis, Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.
Bruno PalhaisLab of Normal and Malignant Hematopoiesis, Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0003-3733-6256
Béatrice LintermansLab of Normal and Malignant Hematopoiesis, Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0003-4842-944X
Sara T'SasCancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium.ORCID 0000-0003-4256-9775
Igor FijalkowskiCancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium.ORCID 0000-0002-3212-5516
Joachim TaminauCancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium.
Muluembet Z AkeleLaboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, Katholieke Universiteit (KU) Leuven, 3000 Leuven, Belgium.
Siska Van BelleLaboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, Katholieke Universiteit (KU) Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-1179-3064
Tom TaghonCancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium.ORCID 0000-0002-5781-0288
Dieter DeforceLaboratory of Pharmaceutical Biotechnology, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0002-0635-661X
Filip Van NieuwerburghLaboratory of Pharmaceutical Biotechnology, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0001-8815-5485
Geert BerxCancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium.ORCID 0000-0001-5770-2458
Panagiotis NtziachristosCancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium.
Zeger DebyserLaboratory for Molecular Virology and Gene Therapy, Department of Pharmaceutical and Pharmacological Sciences, Katholieke Universiteit (KU) Leuven, 3000 Leuven, Belgium.ORCID 0000-0002-3982-1565
Kaat DurinckCancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium.ORCID 0000-0003-1762-5739
Tim PietersLab of Normal and Malignant Hematopoiesis, Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0002-2958-0104
Steven GoossensCancer Research Institute Ghent (CRIG), Ghent University, 9000 Ghent, Belgium.ORCID 0000-0002-5693-8570
Pieter Van VlierbergheLab of Normal and Malignant Hematopoiesis, Center for Medical Genetics, Department of Biomolecular Medicine, Ghent University, 9000 Ghent, Belgium.ORCID 0000-0001-9063-7205

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy. Current intensified therapeutic protocols coincide with severe side effects, and no salvage therapy is available for primary therapy-resistant or relapsed patients. This highlights the need to identify new therapeutic targets in T-ALL. PSIP1, dispensable for normal hematopoiesis, is a dependency factor in

Indexed as

Precursor T-Cell Lymphoblastic Leukemia-LymphomaAdaptor Proteins, Signal TransducingAnimalsCell Line, TumorCell ProliferationElectron Transport Complex IVGene Expression Regulation, LeukemicHumansMiceMitochondriaAdaptor Proteins, Signal TransducingElectron Transport Complex IV

Identifiers

PMID39485844
PMCPMC11529709

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.